Home  /  Resource Library  /  Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia

Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia

ASH 2020: Three year results of a trial examining obinutuzumab combined with ibrutinib and venetoclax for treatment of CLL.